Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBT Avalon GloboCare	$2.13 -6.6%	$2.61	$1.87 ▼ $11.66	$4.07M	-0.02	317,970 shs	39,941 shs
LPCN Lipocine	$3.03 -0.2%	$3.18	$2.68 ▼ $6.17	$16.39M	1.24	34,049 shs	11,660 shs
MTEX Mannatech	$8.68 -4.7%	$8.85	$7.00 ▼ $16.49	$16.48M	0.84	8,942 shs	8,571 shs
SYBX Synlogic	$1.43 -3.7%	$1.36	$0.90 ▼ $1.96	$16.67M	0.52	26,982 shs	37,250 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBT Avalon GloboCare	0.00%	+2.70%	+5.56%	-41.98%	-54.38%
LPCN Lipocine	0.00%	+3.41%	-2.88%	-16.53%	-18.11%
MTEX Mannatech	0.00%	+12.35%	+16.22%	-8.36%	+21.72%
SYBX Synlogic	0.00%	+5.71%	-14.94%	+34.55%	+2.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBT Avalon GloboCare	1.2009 of 5 stars	0.0	2.0	4.3	2.5	1.7	0.0
LPCN Lipocine	3.0306 of 5 stars	3.8	4.0	0.0	3.4	0.0	0.6
MTEX Mannatech	0.4371 of 5 stars	0.0	3.0	0.0	1.7	1.7	0.0
SYBX Synlogic	0.9571 of 5 stars	0.0	3.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBT Avalon GloboCare	0.00	N/A	N/A	N/A
LPCN Lipocine	3.50	Strong Buy	$9.00	197.52% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALBT, MTEX, SYBX, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	LPCN Lipocine	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBT Avalon GloboCare	$1.33M	3.03	N/A	N/A	($11.37) per share	-0.19
LPCN Lipocine	$4.21M	3.90	N/A	N/A	$3.93 per share	0.77
MTEX Mannatech	$117.87M	0.14	$2.04 per share	4.26	$4.57 per share	1.90
SYBX Synlogic	$10K	1,667.25	N/A	N/A	$1.09 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBT Avalon GloboCare	-$7.90M	-$19.96	N/A	∞	N/A	-1,451.94%	N/A	-65.14%	8/18/2025 (Estimated)
LPCN Lipocine	$10K	-$0.87	N/A	∞	N/A	N/A	-23.59%	-21.91%	11/6/2025 (Estimated)
MTEX Mannatech	$2.49M	-$2.04	N/A	∞	N/A	-3.46%	-48.60%	-10.70%	N/A
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	-8.09%	-5.50%	N/A

Latest ALBT, MTEX, SYBX, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALBT Avalon GloboCare	N/A	-$2.02	N/A	-$6.22	N/A	$0.35 million
8/12/2025	Q2 2025	MTEX Mannatech	N/A	-$2.27	N/A	-$2.27	N/A	$25.68 million
8/5/2025	Q2 2025	LPCN Lipocine	-$0.41	-$0.41	N/A	-$0.41	$1.00 million	$0.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBT Avalon GloboCare	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBT Avalon GloboCare	N/A	0.19	0.19
LPCN Lipocine	N/A	12.71	12.71
MTEX Mannatech	0.58	1.11	0.49
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBT Avalon GloboCare	1.42%
LPCN Lipocine	9.11%
MTEX Mannatech	12.98%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
ALBT Avalon GloboCare	37.30%
LPCN Lipocine	6.35%
MTEX Mannatech	41.50%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBT Avalon GloboCare	5	1.89 million	1.19 million	Not Optionable
LPCN Lipocine	10	5.42 million	5.08 million	No Data
MTEX Mannatech	250	1.90 million	1.11 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

ALBT, MTEX, SYBX, and LPCN Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT, MTEX, SYBX, and LPCN Company Descriptions

Avalon GloboCare NASDAQ:ALBT

$2.13 -0.15 (-6.58%)

As of 03:20 PM Eastern

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Lipocine NASDAQ:LPCN

$3.02 -0.01 (-0.17%)

As of 03:08 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Mannatech NASDAQ:MTEX

$8.68 -0.43 (-4.67%)

As of 03:04 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

Synlogic NASDAQ:SYBX

$1.42 -0.06 (-3.72%)

As of 03:20 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time